October 30, 2014

By Jenny Powers

LIVERPOOL, United Kingdom -- October 30, 2014 -- Melanoma-free survival is not affected by the time interval between excision of the primary melanoma lesion and sentinel-node biopsy, according to findings from a retrospective analysis presented today at the 34th Congress of the European Society of Surgical Oncology (ESSO).

“Current guidelines call for sentinel-node biopsy when the melanoma lesion has a Breslow thickness of 1 mm or larger and set the interval at 6 weeks or less,” stated Charlotte Oude Ophuis, MD, PhD student, Erasmus Medical College, Rotterdam, The Netherlands, citing 1 previous report suggesting that a time interval of less than 3 weeks is associated with poorer outcome.

Dr. Oude Ophuis and colleagues analysed data from 928 patients with a positive sentinel-node diagnosis recoded in any of the 9 participating European Organization for Research and Treatment of Cancer Melanoma Group Centers who also had primary excision-date records.

The primary melanoma lesions showed an overall median Breslow thickness of 3.00 mm, and 44% of lesions were ulcerated.

The median patient follow-up was 36 months (range, 1 to 162 months). Median interval between primary excision of the melanoma lesion and sentinel node biopsy was 37 days (5.3 weeks), and 26% of patients had an interval of 8 weeks or more.

The analysis demonstrated that patients undergoing sentinel-node biopsy with an interval of 2 weeks or less between the initial excision and sentinel-node biopsy had a poorer melanoma specific survival (MSS) outcome. The MSS in patients having sentinel-node biopsy within 2 weeks was 66% compared with 70% in patients having sentinel-node biopsy after an interval longer than 2 weeks (hazard ratio [HR] 0.74; 95% confidence interval [CI] 0.56 to 0.98; P = .036).

A 3-week cut-off value was selected that showed the MSS rate was 66% for patients undergoing sentinel-node biopsy within 3 weeks compared with 71% for patients having sentinel-node biopsy at an interval of 3 weeks or more (HR 0.74; 95% CI, 0.56 to 0.96; P = .025). Using a cut-off of a 6-week interval showed no significant differences in MSS (P = .123).

Taken at face value, these data suggested that the interval between primary excision and sentinel-node biopsy was a factor in MSS. Multivariate analysis, however, uncovered 2 confounders. Patients who had primary excision and sentinel-node biopsy within 3 weeks had lesions with a greater median Breslow thickness of 3.75 mm, and ulceration was present in 56% of patients, whereas patients with a time interval between the 2 procedures longer than 3 weeks had lesions with median Breslow thickness of 2.60 mm, and lesion ulceration was present in just 39% of patients.

Multivariate analysis did not confirm time interval between primary excision and sentinel-node biopsy as an independent prognostic factor for MSS. Instead, Breslow thickness greater than 4 versus 2 mm (P< .001) and the presence of ulceration more than 50% versus 30% (P = .001) were confirmed as predictors for poorer MSS.

“In our institution, it is recommended to perform sentinel-node biopsy within 6 weeks of the primary excision, based on relieving patient anxiety; but we try to demonstrate that waiting will not influence the outcome,” commented Dr. Oude Ophuis.

[Presentation title: On Behalf of the EORTC MG: The Interval Between Primary Melanoma Excision and Sentinel Node Biopsy Does Not Affect Survival.Abstract 66]

Log in or register to post comments

DG News saves you time by delivering a short list of medical stories worthy of your time and attention. Our advanced algorithms rank clinical content based on hundreds of data points to surface the most important medical advances impacting your practice each week.